IBN Initiates Coverage of Kairos Pharma Ltd.
Kairos Pharma, Ltd. (KAPA)
Company Research
Source: GlobeNewswire
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts. Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. The company's flagship program, ENV105, is designed to address resistance in anti-androgen and EGFR-based therapies by targeting CD105, a protein that cancer cells produce to evade treatment. This innovative approach has the potential to revitalize existing cancer drugs and deliver lasting benefits for patients. ENV105 is currently in Phase 2 trial for prostate cancer and Phase 1 trial for lung cancer, addressing significant unmet medical needs. Beyond ENV105, Kairos is advancing a broad pipeline
Show less
Read more
Impact Snapshot
Event Time:
KAPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KAPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KAPA alerts
High impacting Kairos Pharma, Ltd. news events
Weekly update
A roundup of the hottest topics
KAPA
News
- Kairos Pharma to Participate in The Microcap Conference in January 2025 [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma to Participate in The Microcap Conference in January 2025Accesswire
- Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical TrialBusiness Wire
- Kairos Pharma Approved to Dual List on Upstream [Yahoo! Finance]Yahoo! Finance
KAPA
Sec Filings
- 12/13/24 - Form 8-K
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- KAPA's page on the SEC website